358 related articles for article (PubMed ID: 29650799)
1. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
Tiacci E; Ladewig E; Schiavoni G; Penson A; Fortini E; Pettirossi V; Wang Y; Rosseto A; Venanzi A; Vlasevska S; Pacini R; Piattoni S; Tabarrini A; Pucciarini A; Bigerna B; Santi A; Gianni AM; Viviani S; Cabras A; Ascani S; Crescenzi B; Mecucci C; Pasqualucci L; Rabadan R; Falini B
Blood; 2018 May; 131(22):2454-2465. PubMed ID: 29650799
[TBL] [Abstract][Full Text] [Related]
2. A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
Zahn M; Marienfeld R; Melzner I; Heinrich J; Renner B; Wegener S; Mießner A; Barth TF; Dorsch K; Brüderlein S; Möller P
Blood; 2017 Mar; 129(11):1480-1490. PubMed ID: 28082443
[TBL] [Abstract][Full Text] [Related]
3. The PTP1B mutant PTP1B∆2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.
Zahn M; Kaluszniak B; Möller P; Marienfeld R
Carcinogenesis; 2021 Apr; 42(4):517-527. PubMed ID: 33382412
[TBL] [Abstract][Full Text] [Related]
4. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
[TBL] [Abstract][Full Text] [Related]
5. Association of JAK-STAT pathway related genes with lymphoma risk: results of a European case-control study (EpiLymph).
Butterbach K; Beckmann L; de Sanjosé S; Benavente Y; Becker N; Foretova L; Maynadie M; Cocco P; Staines A; Boffetta P; Brennan P; Nieters A
Br J Haematol; 2011 May; 153(3):318-33. PubMed ID: 21418178
[TBL] [Abstract][Full Text] [Related]
6. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
Lollies A; Hartmann S; Schneider M; Bracht T; Weiß AL; Arnolds J; Klein-Hitpass L; Sitek B; Hansmann ML; Küppers R; Weniger MA
Leukemia; 2018 Jan; 32(1):92-101. PubMed ID: 28659618
[TBL] [Abstract][Full Text] [Related]
7. Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.
Laurent C; Nicolae A; Laurent C; Le Bras F; Haioun C; Fataccioli V; Amara N; Adélaïde J; Guille A; Schiano JM; Tesson B; Traverse-Glehen A; Chenard MP; Mescam L; Moreau A; Chassagne-Clement C; Somja J; Escudié F; André M; Martin N; Lacroix L; Lemonnier F; Hamy AS; Reyal F; Bannier M; Oberic L; Prade N; Frénois FX; Beldi-Ferchiou A; Delfau-Larue MH; Bouabdallah R; Birnbaum D; Brousset P; Xerri L; Gaulard P
Blood; 2020 Jan; 135(5):360-370. PubMed ID: 31774495
[TBL] [Abstract][Full Text] [Related]
8. Analysis of JAK-STAT signaling pathway genes and their microRNAs in the intestinal mucosa of genetically disparate chicken lines induced with necrotic enteritis.
Truong AD; Rengaraj D; Hong Y; Hoang CT; Hong YH; Lillehoj HS
Vet Immunol Immunopathol; 2017 May; 187():1-9. PubMed ID: 28494922
[TBL] [Abstract][Full Text] [Related]
9. Gene and protein expression profiles of JAK-STAT signalling pathway in the developing brain of the Ts1Cje down syndrome mouse model.
Lee HC; Md Yusof HH; Leong MP; Zainal Abidin S; Seth EA; Hewitt CA; Vidyadaran S; Nordin N; Scott HS; Cheah PS; Ling KH
Int J Neurosci; 2019 Sep; 129(9):871-881. PubMed ID: 30775947
[No Abstract] [Full Text] [Related]
10. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
11. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line.
Baus D; Nonnenmacher F; Jankowski S; Döring C; Bräutigam C; Frank M; Hansmann ML; Pfitzner E
Leukemia; 2009 Oct; 23(10):1885-93. PubMed ID: 19440213
[TBL] [Abstract][Full Text] [Related]
12. Mining for JAK-STAT mutations in cancer.
Constantinescu SN; Girardot M; Pecquet C
Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
[TBL] [Abstract][Full Text] [Related]
13. A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.
Durand M; Cabaud Gibouin V; Duplomb L; Salmi L; Caillot M; Sola B; Camus V; Jardin F; Garrido C; Jego G
J Exp Clin Cancer Res; 2024 May; 43(1):148. PubMed ID: 38773631
[TBL] [Abstract][Full Text] [Related]
14. Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma.
Wang X; Liao X; Yu T; Gong Y; Zhang L; Huang J; Yang C; Han C; Yu L; Zhu G; Qin W; Liu Z; Zhou X; Liu J; Han Q; Peng T
Int J Oncol; 2019 Oct; 55(4):805-822. PubMed ID: 31485610
[TBL] [Abstract][Full Text] [Related]
15. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type.
Lee S; Park HY; Kang SY; Kim SJ; Hwang J; Lee S; Kwak SH; Park KS; Yoo HY; Kim WS; Kim JI; Ko YH
Oncotarget; 2015 Jul; 6(19):17764-76. PubMed ID: 25980440
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.
Manso R; Sánchez-Beato M; González-Rincón J; Gómez S; Rojo F; Mollejo M; García-Cosio M; Menárguez J; Piris MA; Rodríguez-Pinilla SM
Br J Haematol; 2018 Nov; 183(3):497-501. PubMed ID: 29076126
[No Abstract] [Full Text] [Related]
17. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6.
Mottok A; Renné C; Willenbrock K; Hansmann ML; Bräuninger A
Blood; 2007 Nov; 110(9):3387-90. PubMed ID: 17652621
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma.
Kleppe M; Tousseyn T; Geissinger E; Kalender Atak Z; Aerts S; Rosenwald A; Wlodarska I; Cools J
Haematologica; 2011 Nov; 96(11):1723-7. PubMed ID: 21791476
[TBL] [Abstract][Full Text] [Related]
19. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma.
Pérez C; González-Rincón J; Onaindia A; Almaráz C; García-Díaz N; Pisonero H; Curiel-Olmo S; Gómez S; Cereceda L; Madureira R; Hospital M; Suárez-Massa D; Rodriguez-Peralto JL; Postigo C; Leon-Castillo A; González-Vela C; Martinez N; Ortiz-Romero P; Sánchez-Beato M; Piris MÁ; Vaqué JP
Haematologica; 2015 Nov; 100(11):e450-3. PubMed ID: 26294736
[No Abstract] [Full Text] [Related]
20. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
Szydłowski M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Derezińska E; Hoser G; Wasilewska D; Szymańska-Giemza O; Jabłońska E; Białopiotrowicz E; Sewastianik T; Polak A; Czardybon W; Gałęzowski M; Windak R; Zaucha JM; Warzocha K; Brzózka K; Juszczyński P
Blood; 2017 Sep; 130(12):1418-1429. PubMed ID: 28698206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
